Sai Parenteral's (NSE:SAIPARENT) Stock Based Compensation: ₹0 Mil (TTM As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAIPARENT Sai Parenteral's Ltd NSE:SAIPARENT
14 GF Score
Price ₹569.70
! 7 Warning Signs
View Full Analysis

What is Sai Parenteral's Stock Based Compensation?

Sai Parenteral's NSE:SAIPARENT +5.28% 14 Stock Based Compensation is ₹0 Mil as of Sep. 2025. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review.

Sai Parenteral's's Stock Based Compensation for the six months ended in Sep. 2025 was ₹0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2025 was ₹0 Mil.

Sai Parenteral's Stock Based Compensation Related Terms

Sai Parenteral's Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Sai Parenteral's's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Parenteral's Stock Based Compensation Chart

Sai Parenteral's Annual Data
Trend Mar23 Mar24 Mar25
Stock Based Compensation
0.00 0.00 0.00

Sai Parenteral's Semi-Annual Data
Mar23 Mar24 Mar25 Sep25
Stock Based Compensation 0.00 0.00 0.00 0.00
NSE:SAIPARENT
14GF Score
Sai Parenteral's Ltd NSE:SAIPARENT
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sai Parenteral's Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0 Mil.

What does a Stock Based Compensation of ₹0 Mil mean?
Sai Parenteral's (NSE:SAIPARENT) has a Stock Based Compensation of ₹0 Mil as of Sep. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Sai Parenteral's and its competitors.
Is Sai Parenteral's' Stock Based Compensation too high?
Sai Parenteral's' current Stock Based Compensation is ₹0 Mil. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' Stock Based Compensation compare to LLY and JNJ?
Sai Parenteral's' Stock Based Compensation of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Sai Parenteral's and its competitors. Sai Parenteral's's current Stock Based Compensation is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current Stock Based Compensation of ₹0 Mil. The current Stock Based Compensation is ₹0 Mil. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current Stock Based Compensation is ₹0 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sai Parenteral's Business Description

Other Exchanges 544742:India
Address Plot No 39, 5th floor, Lavanya Arcade Jayabheri Enclave, Gachibowli, K.V.Rangareddy, Seri Lingampally, Hyderabad, TG, IND, 500032
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score

Get the complete analysis for NSE:SAIPARENT

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹569.70
Price